Search

Your search keyword '"Sofer, Orit"' showing total 15 results
Start Over Author "Sofer, Orit"
15 results on '"Sofer, Orit"'

1. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

2. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Author

Levy, Ilana, primary, Lavi, Avital, additional, Zimran, Eran, additional, Grisariu, Sigal, additional, Aumann, Shlomzion, additional, Itchaki, Gilad, additional, Berger, Tamar, additional, Raanani, Pia, additional, Harel, Reut, additional, Aviv, Ariel, additional, Lavi, Noa, additional, Zuckerman, Tsila, additional, Shvidel, Lev, additional, Jarchowsky, Osnat, additional, Ellis, Martin, additional, Herzog Tzarfati, Katrin, additional, Koren-Michowitz, Maya, additional, Sherf, Yehonatan, additional, Levi, Itai, additional, Sofer, Orit, additional, Shpilberg, Ofer, additional, Dally, Nagib, additional, Suriu, Celia, additional, Braester, Andrei, additional, Ben Barouch, Sharon, additional, Leiba, Merav, additional, Goldstein, Daniela, additional, Sarid, Nadav, additional, Yeganeh, Shay, additional, Halloun, Jabour, additional, Mittelman, Moshe, additional, and Tadmor, Tamar, additional

Published
2021
Full Text
View/download PDF

3. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Goldhecht, Yair, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit, additional, Horwitz, Netanel, additional, Gutwein, Odit, additional, Gurion, Ronit, additional, Itchaki, Gilad, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Zektser, Miri, additional, Tadmor, Tamar, additional, Dally, Nagib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2020
Full Text
View/download PDF

4. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit Ringelstein, additional, Gutwein, Odit, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Dally, Najib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

5. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Author

Perry, Chava, primary, Ben Barouch, Sharon, additional, Goldschmidt, Neta, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Bairey, Osnat, additional, Lavi, Noa, additional, Horowitz, Netanel, additional, Avigdor, Avraham, additional, Lebel, Eyal, additional, Sofer, Orit, additional, Ram, Ron, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

7. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

Author

Segman, Yafit, Ribakovsky, Elena, Avigdor, Abraham, Goldhecht, Yair, Vainstein, Vladimir, Goldschmidt, Neta, Harlev, Shimrit, Horwitz, Netanel, Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Zektser, Miri, Tadmor, Tamar, Dally, Nagib, Filanovsky, Kalman, Leiba, Merav, and Sarid, Nadav

Subjects
DIFFUSE large B-cell lymphomas, PROGRESSION-free survival, LYMPHOMAS, HODGKIN'S disease
Abstract

The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. [Prevalence and etiology of anemia in an institutionalized geriatric population].

Author

Chernetsky A, Sofer O, Rafael C, and Ben-Israel J

Subjects
Aged, Anemia etiology, Anemia, Iron-Deficiency diagnosis, Chronic Disease, Folic Acid Deficiency complications, Humans, Institutionalization, Israel epidemiology, Kidney Failure, Chronic complications, Prevalence, Vitamin B 12 Deficiency complications, Anemia epidemiology, Homes for the Aged
Abstract

Objective: Anemia is a common problem in the elderly, but its etiology in this age group is not well known, nor is its correlation with the mental and functional states. The objectives of the present study were to determine the prevalence of anemia in a large institutionalized geriatric population, to diagnose the etiology, and to analyze the correlation of anemia with the nutritional, mental and functional status., Methods: The study was performed in a 970 bed multilevel geriatric complex, from which 481 residents were randomly chosen. Their mean age was 81.4 +/- 8.7 years, and 46 of these residents were independent, 162 frail, and 273 nursing home patients., Results: High prevalence of anemia (31.4%) was found, but, in more than half of the cases, the anemia was mild. The most common diagnosis was anemia of chronic disorders (65.6%), followed by anemia of chronic renal failure (13.2%). Anemia primarily due to iron, vitamin B12 or folate deficiency was found to be only 4%. In 15.9% of these cases the main cause of anemia could not be resolved. No correlation with the nutritional or cognitive states was found, but the functional state was highly and significantly inversely correlated with the presence of anemia., Conclusions: Anemia in institutionalized elderly is mostly the consequence of other chronic diseases. Further studies are required to determine whether a low functional state is an independent risk factor for anemia in old age.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results